📰 Nasdaq Oric News
Nasdaq Oric News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Oric. Real-time updates on events, politics, business and more.
April 24, 2024
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) and GH Research (NASDAQ:GHRS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends. Volatility and Risk ORIC Pharmaceuticals has a […]
April 2, 2024
Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) have been assigned an average recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the […]
February 29, 2024
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) – Equities researchers at Cantor Fitzgerald issued their FY2023 earnings estimates for shares of ORIC Pharmaceuticals in a note issued to investors on Monday, February 26th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings per share of ($1.90) for the year. Cantor Fitzgerald has […]
February 23, 2024
Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $10.12, but opened at $10.43. ORIC Pharmaceuticals shares last traded at $10.52, with a volume of 36,713 shares. Analyst Ratings Changes A number of research analysts have weighed in on […]
February 14, 2024
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has been assigned a consensus rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last […]
February 9, 2024
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) CEO Jacob Chacko sold 13,958 shares of the company’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $12.12, for a total transaction of $169,170.96. Following the completion of the sale, the chief executive officer now owns 794,586 shares […]
February 6, 2024
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report)’s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $12.03 and last traded at $11.92, with a volume of 71670 shares traded. The stock had previously closed at $11.48. Wall Street Analyst Weigh In ORIC has been the […]
January 24, 2024
Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $10.02, but opened at $10.63. ORIC Pharmaceuticals shares last traded at $10.60, with a volume of 85,540 shares. Analyst Upgrades and Downgrades Several equities analysts recently issued reports on ORIC […]
January 8, 2024
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a research note issued on Monday, RTT News reports. They presently have a $12.00 price objective on the stock. Wedbush’s price objective would indicate a potential upside of 42.52% from the stock’s current price. Separately, HC […]
December 26, 2023
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has been given a consensus recommendation of “Buy” by the seven research firms that are presently covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock […]